Given M-I’s role in suppressing tumor proliferation and remodeling the tumor immune environment, M-I could be evaluated in combination with chemotherapy or immune checkpoint inhibitors to enhance efficacy in TNBC treatment. Here, MITF is linked to neoplasm.